Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Flaherty, Lawrence E ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Biochemotherapy; Cisplatin; Dacarbazine; Interferon; Interleukin 2; Metastatic melanoma; Vinblastine

Indexed keywords

CISPLATIN; DACARBAZINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; VINBLASTINE; ALPHA INTERFERON; BLEOMYCIN; CARMUSTINE; INTERLEUKIN 2; LOMUSTINE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; METASTASIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; VINBLASTINE;

EID: 0033839721     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ahmann DL, Creagan ET, Hahn RG et al. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989;63:224-227.
2. Flaherty L, Unger J, Liu P et al. Gender differences and predictors of survival in patients with metastatic malignant melanoma of SWOG trials [abstract]. Proc Am Soc Clin Oncol 1996;15:433.
3. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7-17.
4. Kirkwood J, Ibrahim J, Sondak V et al. Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high-and low-dose IFN-α 2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1999;18:537a.
5. Balch C, Reintgen D, Kirkwood J et al. Cutaneous melanoma. In: Cancer: Principles and Practice of Oncology (5th ed.). DeVita V, Hellman S, Rosenberg S, eds. Philadelphia: JB Lippincott Co, 1997:1947-1994.
6. Mastrangelo M, Bellet R, Kane M et al. Chemotherapy of melanoma. In: The Chemotherapy Source Book. Perry M, ed. Baltimore: Williams & Wilkins, 1992:886-907
7. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastacic cancer. Cancer 1998;83:797-805.
8. Kirkwood JM, Ernstoff MS, Davis CA et al. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985;103:32-36.
9. Kirkwood JM, Ernstoff M. Melanoma: therapeutic options with recombinant interferons. Semin Oncol 1985;12:7-12.
10. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
11. Legha SS, Ring S, Papadopoulos N et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989;64: 2024-2029.
12. McClay EF, Mastrangelo MJ, Bellet RE et al. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987;71:465-469.
13. Del Prete SA, Maurer LH, O'Donnell J et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-1405.
14. Murren JR, DeRosa W, Durivage HJ et al. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991;67:1514-1517.
15. Fletcher WS, Green S, Fletcher JR et al. Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study. Am J Clin Oncol 1988;11:589-593.
16. Seigler HF, Lucas VS Jr, Pickett NJ et al. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 1980;46:2346-2348.
17. York RM, Foltz AT. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 1988;61:2183-2186.
18. McClay EF, Mastrangelo MJ, Berd D et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992;50:553-556.
19. Flaherty LE, Liu PY, Mitchell MS et al. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group (SWOG-8921). Am J Clin Oncol 1996;19:108-113.
20. Margolin KA, Liu PY, Flaherty LE et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 1998;16:664-669.
21. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group. Cancer 1989;63:1676-1680.
22. Fletcher WS, Daniels DS, Sondak VK et al. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study. Am J Clin Oncol 1993;16:359-362.
23. Saxman S, Meyers M, Chapman P et al. A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1999;18:536a.
24. Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992;327:516-523.
25. Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2083-2090.
26. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16:1743-1751.
27. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9:1403-1408.
28. Thomson DB, Adena M, McLeod GR et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993;3:133-138.
29. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12:806-811.
30. Kirkwood JM, Ernstoff S, Giuliano A et al. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst 1990;82:1062-1063.
31. Atkins MB, O'Boyle KR, Sosman JA et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-1560.
32. Antoine EC, Benhammouda A, Bernard A et al. Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 1997;3[suppl 1]:S16-S21.
33. Richards JM, Mehta N, Ramming K et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-1343.
34. Legha SS, Ring S, Eton O et al. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997;3[suppl 1]:S9-S15.
35. Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588.
36. McDermott DF, Mier JW, Lawrence DP et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (IL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1998;17:507a.
37. O'Day S, Boasberg P, Guo M et al. Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-IL-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM) [abstract]. Proc Am Soc Clin Oncol 1997;16:490a.
38. Flaherty LE, Robinson W, Redman BG et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993;71:3520-3525.
39. Thompson JA, Gold PJ, Markowitz DR et al. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 1997;3[suppl 1]:S29-S34.
40. Atzpodien J, Lopez Hanninen E, Kirchner H et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995;31A: 876-881.
41. Bernengo MG, Doveil GC, Bertero M et al. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma - a pilot study. Melanoma Res 1996;6:257-265.
42. Guida M, Latorre A, Mastria A et al. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Eur J Cancer 1996;32A:730-733.
43. Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-2929.
44. Allen I, Kupelnick B, Kumashiro M. Efficacy of interleukin-2 in the treatment of metastatic melanoma - systemic review and metastasis-analysis. Cancer Therapeutics 1998;1:168-173.
45. Legha SS, Ring S, Eton O et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-1759.